Antitumor activity of dioxadet compared with cisplatin activity in ascitic ovarian tumor rat model

Voprosy Onkologii

Volumn 57, Issue 6, 2011, Pages 771-774

  Bespalov, V G ^a   Belyaeva, O A ^a   Panchenko, A V ^a   Stukov, A N ^a   Gershanovich, M L ^a   Murazov, Ya G ^a   Konkov, S A ^a   Kilmaeva, N E ^a   Krylova, I M ^a   Mironyuk, T A ^a   Latipova, D X ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DIAXADET; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES CELL; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; LIFESPAN; NONHUMAN; OVARY TUMOR; RAT; SURVIVAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; ASCITES; CISPLATIN; FEMALE; OVARIAN NEOPLASMS; RATS; RATS, WISTAR; TREATMENT OUTCOME; TRIAZINES;

EID: 84857093328     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Echarri Gonzalez M.J., Green R., Muggia F.M. Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when? // Oncology (Williston Park).-2011.-Vol. 25.-P. 156-165.
2. Nelson G., Lucero C.A., Chu P. et al. Intraperitoneal chemotherapy for advanced ovarian and peritoneal cancers in patients following interval debulking surgery or primary cytoreductive surgery: Tom Baker Cancer Centre experience from 2006 to 2009 // J. Obstet. Gynaecol. Can.-2010.-Vol. 32.-P. 263-269.